e19534 Background: Despite the availability of new therapies for follicular lymphoma (FL),
there are limited data on the real-world treatment (tx) of FL in a contemporary cohort of …

e19044 Background: FL often becomes relapsed or refractory (R/R) to treatment. This study
aimed to analyze TTNT, HCRU, and cost of care in FL. Methods: A retrospective study was …

Background: Follicular lymphoma (FL) represents 70% of all indolent non-Hodgkin
lymphomas and it is widely recognized that FL is a heterogeneous disease, with patients …

Follicular lymphoma (FL) is the second most common lymphoma, and by virtue of its
chronicity, may be the most prevalent and most treated lymphoma in the United States …

8049 Background: The National LymphoCare Study (NLCS) collects data on disease
presentation, treatment patterns, and clinical outcomes for 2736 patients with with follicular …

Background: Follicular lymphoma (FL) is the second most common non-Hodgkin lymphoma
(NHL) and the most common indolent NHL. Rituximab-based therapy has been a mainstay …

Introduction: Follicular lymphoma (FL) accounts for about 35% of all non-Hodgkin
lymphomas and 70% of indolent lymphomas in the United States. Despite relatively high 1L …

Background Few studies have evaluated real-world treatment patterns and survival in
follicular lymphoma (FL). This study evaluated these outcomes among newly diagnosed …

7527 Background: Initial treatment strategies in FL include observation (obs), rituximab (R),
chemotherapy±R, and XRT. A recent study suggests initial therapy may impact FL survival …

Over the past several decades, tremendous progress has been made in the treatment of
follicular lymphoma. The addition of rituximab to chemotherapy led to significant …